Moderna showcases AI and mRNA tech in latest R&D update
Moderna showcases AI and mRNA tech in latest R&D update
Updated at: June 25, 2026 at 06:00 AM
Moderna is redefining itself as a digital-first biotech company, leveraging artificial intelligence to transform the landscape of mRNA drug development.
By treating mRNA as the 'software of life,' Moderna uses AI to optimize the design and manufacturing of vaccines at unprecedented speeds.
Through a strategic partnership with OpenAI, the company has integrated custom AI tools across its operations, from legal departments to complex research analytics.
To support this vision, Moderna launched an AI Academy with Carnegie Mellon University to ensure its workforce remains at the cutting edge of technological innovation.
Beyond technology, Moderna is successfully expanding its medical pipeline.
By combining these advanced computational capabilities with a diverse range of clinical programs, Moderna is proving that its platform technology can extend far beyond its initial success, positioning the company as a leader in the next generation of global medicine.
